Davod Ilbeigi

Davod Ilbeigi

Auto-generated profile, based on publicly available information

Davod Ilbeigi

Torbat Heydariyeh University of Medical Sciences

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Endocrine, Metabolic & Immune Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
RAReza Afrisham
Reza Afrisham
MPMaliheh Paknejad
Maliheh Paknejad
DIDavod Ilbeigi
Davod Ilbeigi
SSSahar Sadegh-Nejadi
Sahar Sadegh-Nejadi
SGSattar Gorgani-Firuzjaee
Sattar Gorgani-Firuzjaee
MVmahmoud vahidi
mahmoud vahidi
Objective: Fetuin-A serves a dual function; its high levels are associated with metabolic syndrome, type 2 diabetes, obesity, insulin resistance, and nonalcoholic fatty liver disease, and on the other hand, it serves as a potent inhibitor of ectopic vascular calcification. Due to the opposing findings, the aim of the current study was to investigate serum fetuin-A levels in men with coronary artery disease (CAD). Methods: In the case-control study, anthropometric and biochemical parameters were determined in 83 men (43 CAD patients and 40 control subjects). At last, the serum fetuin-A levels were measured using the fetuin-A human enzyme-linked immunosorbent assay (ELISA) kit. Results: A significant difference was detected among the two groups for triglyceride and cholesterol levels (P=0.003 and P=0.002, respectively). The mean fetuin-A levels were determined 230.57 ± 63.76 and 286.35 ± 64.07 μg/ml for the control group and the CAD patients, respectively (P<0.001). Fetuin- A was significantly correlated to the severity of CAD (r 0.393, P<0.001) and associated with the risk of CAD in subjects (OR [CI] = 1. 144 [1.060-1. 235]; p = 0.001). A cut-off value of 237.4 μg/ml had good sensitivity (76.7%) and specificity (65.0%) for differentiating between two groups [area under curve (AUC) = 0.732 (CI=0.621-0.842); p < 0.001]. Conclusion: Our results indicated that fetuin-A levels were positively correlated to the severity of CAD. The findings suggest that there is a possible link between pathogenic mechanisms of atherosclerosis and fetuin-A; however, more investigations are needed in this regard.

1 January 2025 in BioMed Research International
Verified
Journal Article
Open access
HSHajar Shokri-Afra
Hajar Shokri-Afra
FJFatemeh Saber Jeyvan
Fatemeh Saber Jeyvan
ZBZeinab Barartabar
Zeinab Barartabar
PKParisa Khanicheragh
Parisa Khanicheragh
EAElham Yousefi Abdolmaleki
Elham Yousefi Abdolmaleki
YMYalda Malekzadegan
Yalda Malekzadegan
Sirtuin 1 (SIRT1) is a crucial regulator of cellular processes, including inflammation, metabolism, and stress responses, playing a significant role in the body′s defense mechanisms. During SARS‐CoV‐2 infection, SIRT1 plays a crucial role in modulating the immune response. This protein helps to enhance the antiviral response through deacetylating key transcription factors and regulating proinflammatory cytokines, thereby reducing the cytokine storm (an overwhelming immune response) associated with severe COVID‐19 cases. SIRT1 influences the expression of angiotensin‐converting enzyme 2 (ACE2), the primary receptor for SARS‐CoV‐2, thereby potentially mitigating viral entry and replication. Natural activators of SIRT1, such as resveratrol, have been shown to enhance its activity, offering promising avenues for therapeutic interventions aimed at bolstering the immune response during COVID‐19. Understanding the multifaceted role of SIRT1 in human defense mechanisms against SARS‐CoV‐2 could pave the way for innovative strategies to manage COVID‐19 and similar viral infections, emphasizing the importance of SIRT1 as a potential target for future therapeutic approaches.

1 October 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HRHossain Rezayee
Hossain Rezayee
MFMohammad Ali Fahmidehkar
Mohammad Ali Fahmidehkar
FBFarimah Beheshti
Farimah Beheshti
MGMohsen Ghoryani
Mohsen Ghoryani
YYYaser Yousefpoor
Yaser Yousefpoor
DIDavod Ilbeigi
Davod Ilbeigi
Objective: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide. This study aims to investigate the effects of crocin on lipid profile, hepatic lipid accumulation, and antioxidant status in a rat model of non-alcoholic fatty liver induced by a high-fat diet. Materials and methods: Forty-two male Wistar rats were divided into six groups, each containing seven rats. Fatty liver was induced by feeding a high-fat diet for eight weeks. Subsequently, the treatment groups received intraperitoneal crocin for four weeks. The groups were then evaluated for changes in serum lipid profiles, liver function enzymes in serum, oxidative stress biomarkers and histopathological alterations in liver tissue. Results: High-fat diet feeding resulted in significant hepatic lipid accumulation, elevated serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels, increased hepatic malondialdehyde and nitrite concentrations, and impaired antioxidant enzyme activities. Histological analysis demonstrated hepatocellular steatosis, inflammatory infiltration, and hepatic structural alterations. Crocin treatment significantly attenuated lipid accumulation, normalized serum liver enzyme levels, reduced oxidative stress markers, and enhanced antioxidant enzyme activities. Histopathological evaluation further confirmed marked improvement in liver tissue morphology. Conclusion: The results of the present study demonstrate that Crocin exerts protective effects against NAFLD, highlighting its potential as a therapeutic agent for diet-induced fatty liver disease.